India Panel Recommends CL For BMS's Sprycel Leukemia Drug
This article was originally published in PharmAsia News
Executive Summary
An India regulatory panel reportedly has recommended the government use its compulsory license to enable two generic versions of Bristol-Myers Squibb's Sprycel (dasatinib) for treating a form of leukemia.